Foghorn Therapeutics

Biotech · Private

Chromatin regulatory proteins that modulate gene expression programs in cancer cells

foghorntx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
18 granted · 22 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2711KATHERA BIOSCIENCE INC.——
2712ENCUE INC.——
2713Immune Response BioPharma, Inc.—$1.0B
2714Foghorn Therapeutics——
2715COGNOSCI, INC.——
2716IMPLICYTE, INC.——
2717OnRamp Digital, Inc.—$360K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 18 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.